EP 235: Inside Alzheimer’s disease: Blood biomarkers and predicting symptoms with Suzanne Schindler

EP 235: Inside Alzheimer’s disease: Blood biomarkers and predicting symptoms with Suzanne Schindler

by Sano Genetics

Life & Natural Systems Medicine & Health MKJNeurology and clinical neurophysiologyMKJDAlzheimer’s, dementia, Parkinson’s disease and other neurodegenerative diseases
🎙 Sano Genetics 👥 942 📅 April 16, 2026 ⏱ 43 min 👁 114 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

Alzheimer's diseasep-tau217blood biomarkersAPOEclock models

Summary

In this episode of The Genetics Podcast, host Patrick Short interviews Dr. Suzanne Schindler, an Associate Professor of Neurology at Washington University in St. Louis. The conversation focuses on the use of blood-based biomarkers, particularly p-tau217, to detect and stage Alzheimer’s disease. Dr. Schindler explains the distinction between Alzheimer’s disease and dementia, emphasizing that Alzheimer’s is defined by the presence of amyloid plaques and tau tangles. She describes how p-tau217 levels rise in blood and cerebrospinal fluid years before symptom onset, and how ‘clock models’ can estimate the timing of symptom onset based on biomarker trajectories. The discussion covers the role of the APOE gene, particularly the E4 allele, in increasing amyloid accumulation, and notes that once a tipping point of amyloid is reached, APOE carriers and non-carriers show similar trajectories. Dr. Schindler also touches on sex differences in tau pathology, rare cases where amyloid and tau pathology diverge, and the potential of combining biomarkers to improve predictions. The episode concludes with an overview of therapeutic strategies, including amyloid-targeting and tau-targeting treatments, and the challenges of targeting inflammation and APOE.

180 words

Critical Evaluation

Value of the Information & Strength of the Argument

The value of the information is high, as it provides an expert perspective on cutting-edge research in Alzheimer’s disease biomarkers. The discussion is well-structured, with clear explanations of complex concepts such as the relationship between amyloid and tau pathology, and the utility of p-tau217 in predicting disease progression. The argumentation is solid, grounded in the speaker’s expertise and reference to published studies, though some points are presented as open questions, which is appropriate given the evolving nature of the field.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is strong, with the speaker citing specific studies and mechanisms. The quality of sources is high, as the speaker is a leading researcher in the field. The title accurately reflects the content, focusing on blood biomarkers and symptom prediction. No external sources are explicitly cited in the video, but the speaker’s authority and the alignment with published literature support the reliability. The adequacy between title and content is excellent.

167 words

Title / Content Match

The title accurately reflects the content, which focuses on blood biomarkers (p-tau217) and predicting Alzheimer's symptoms.

Quality & Reliability

8/10

The discussion is led by a domain expert (Associate Professor of Neurology) and covers established scientific concepts and recent research findings. The claims are generally consistent with current scientific understanding, though some topics (e.g., sex differences, APOE-tau interactions) are presented as open questions. No primary data is presented, but the expert's authority and the alignment with published literature support a high reliability score.

Chapters

Contribution & Novelties

The video provides an expert overview of recent advances in Alzheimer’s disease biomarkers, particularly the use of p-tau217 and clock models to predict symptom onset. It offers insights into the practical applications of these biomarkers in clinical trials and patient care, and discusses ongoing research questions such as the role of APOE and sex differences. The discussion is valuable for researchers and clinicians seeking to understand the current state of biomarker-based approaches.

Pour aller plus loin :

123 words

Radar Profile

The radar profile shows high scores in information quantity, quality, and reliability, with a slightly lower score in technical level, indicating that the content is accessible to a broad audience while maintaining scientific depth.

Reliability 8/10